Total Funding
60
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
21998
2seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies.
Acquired by 
Bristol-Myers Squibb
- Susan Abu-Absi: Chief Technology & Manufacturing Officer
- Kathy Wilkinson: Chief People Officer
About the Company
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline.
It was established in Cambridge, Massachusetts in 2021.
